Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Y.S.P. Southeast Asia Holding Bhd EV-to-EBIT?
Y.S.P. Southeast Asia Holding BhdXKLS:7178 70 EV-to-EBIT is 4.32 as of Aug. 28, 2026, which is 37% below its 10-year median of 6.84. GuruFocus rates XKLS:7178 with a GF Score™ of 70/100 and a GF Value™ of RM2.32 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, Y.S.P. Southeast Asia Holding Bhd ranks better than 88.86% on this metric.
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Y.S.P. Southeast Asia Holding Bhd's Enterprise Value for the quarter that ended in Jun. 2026 was RM185.4 Mil.
Y.S.P. Southeast Asia Holding Bhd's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM42.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd EV-to-EBIT Related Terms
Y.S.P. Southeast Asia Holding Bhd EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd EV-to-EBIT Chart
XKLS:7178 vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Y.S.P. Southeast Asia Holding Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y.S.P. Southeast Asia Holding Bhd EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Y.S.P. Southeast Asia Holding Bhd's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Y.S.P. Southeast Asia Holding Bhd's EV-to-EBIT falls into.
Y.S.P. Southeast Asia Holding Bhd's current Enterprise Value is RM182.6 Mil.
Y.S.P. Southeast Asia Holding Bhd's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM42.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) has a EV-to-EBIT of 4.32 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. This is 37% below median its historical median of 6.84. Over the past decade, Y.S.P. Southeast Asia Holding Bhd's EV-to-EBIT has ranged from 4.06 to 12.56. According to the industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #77 out of 691 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Y.S.P. Southeast Asia Holding Bhd's EV-to-EBIT too high?
Y.S.P. Southeast Asia Holding Bhd's current EV-to-EBIT of 4.32 is 37% below median its 10-year median of 6.84. Over the past 10 years, this metric has ranged from a low of 4.06 to a high of 12.56. The Drug Manufacturers industry median EV-to-EBIT is 15.71. Y.S.P. Southeast Asia Holding Bhd's value of 4.32 is 72.5% below this industry median. Based on the distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #77 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Y.S.P. Southeast Asia Holding Bhd has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Y.S.P. Southeast Asia Holding Bhd's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #77 out of 691 companies for EV-to-EBIT. This places Y.S.P. Southeast Asia Holding Bhd in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.71. Y.S.P. Southeast Asia Holding Bhd's value of 4.32 is 72.5% below this benchmark. Historically, Y.S.P. Southeast Asia Holding Bhd's own EV-to-EBIT has ranged from 4.06 to 12.56 over the past decade. While the company's 10-year median is 6.84 vs. the industry median of 15.71, Y.S.P. Southeast Asia Holding Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Y.S.P. Southeast Asia Holding Bhd's current EV-to-EBIT of 4.32 is 72.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Y.S.P. Southeast Asia Holding Bhd's current EV-to-EBIT is 4.32, which is 37% below median its own 10-year median of 6.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Y.S.P. Southeast Asia Holding Bhd stock overvalued right now?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) is currently considered Modestly Undervalued. The stock's GF Value™ is RM2.32, compared to a current price of RM2.02 — trading 12.9% below its estimated fair value. The current EV-to-EBIT is 4.32, which is 37% below median its 10-year median of 6.84 and 72.5% below the Drug Manufacturers industry median of 15.71. Y.S.P. Southeast Asia Holding Bhd's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Y.S.P. Southeast Asia Holding Bhd (XKLS:7178), the current EV-to-EBIT is 4.32 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Overvalued in 2026?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd stock appears to be undervalued.
The current stock price of RM2.02 is trading 12.9% below its estimated GF Value™ of RM2.32.
GuruFocus considers Y.S.P. Southeast Asia Holding Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7178:
EV-to-EBIT: 4.32 (37% below median its 10-year median of 6.84)
GF Value™: RM2.32 vs. price of RM2.02 (12.9% below fair value)
Industry Position: 72.5% below the Drug Manufacturers median (#77 of 691)
No single metric tells the full story. See the XKLS:7178 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. The company operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trading in various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is derived from Malaysia.
70GF Score
Get the complete analysis for XKLS:7178
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7178 has been successfully added to your 
